Drug Profile
Iron deficiency anaemia therapeutic - Fe3 Medical
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Fe3 Medical
- Class Antianaemics; Iron compounds
- Mechanism of Action Iron replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Iron deficiency anaemia
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Iron deficiency anaemia in USA (Transdermal)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Iron deficiency anaemia in USA (Transdermal, Patch)
- 02 Mar 2016 Preclinical trials in Iron deficiency anaemia in USA (Transdermal)